137 related articles for article (PubMed ID: 12893358)
1. Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma.
Lee KL; Terris MK
Urology; 2003 Aug; 62(2):351. PubMed ID: 12893358
[TBL] [Abstract][Full Text] [Related]
2. Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.
Anda T; Honda M; Ishihara T; Kamei T
Neurol Med Chir (Tokyo); 2014; 54(4):327-30. PubMed ID: 24201100
[TBL] [Abstract][Full Text] [Related]
3. Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy.
Nicosia L; Bucpapaj R; Barresi V; Damante R; Napoli G; Ghimenton C; Giaj-Levra N; Cancedda M; Flaminio S; Figlia V; Alongi F
Neurochirurgie; 2021 Apr; 67(2):193-197. PubMed ID: 33190809
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
Maru S; Uchino H; Osawa T; Chiba S; Mouri G; Sazawa A
PLoS One; 2018; 13(5):e0197252. PubMed ID: 29795595
[TBL] [Abstract][Full Text] [Related]
5. Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer.
Tsutsui T; Miyashita K; Sabit H; Fukui I; Hayashi Y; Mizokami A; Ikeda H; Nagatani H; Nakada M
World Neurosurg; 2016 Jul; 91():670.e1-6. PubMed ID: 27046016
[TBL] [Abstract][Full Text] [Related]
6. Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma.
Harland TA; Freeman JL; Davern M; McCracken DJ; Celano EC; Lillehei K; Olson JJ; Ormond DR
J Neurooncol; 2018 Jan; 136(2):327-333. PubMed ID: 29081037
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
Lawrentschuk N; Fernandes K; Bell D; Barkin J; Fleshner N
J Urol; 2011 Mar; 185(3):848-54. PubMed ID: 21239017
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
9. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.
Moul JW; Fowler JE
Urology; 2003 Dec; 62(6 Suppl 1):20-8. PubMed ID: 14706505
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.
Lubgan D; Rutzner S; Lambrecht U; Rössler K; Buchfelder M; Eyüpoglu I; Fietkau R; Semrau S
J Neurooncol; 2017 Sep; 134(2):407-416. PubMed ID: 28667597
[TBL] [Abstract][Full Text] [Related]
11. [Recurrent meningioma].
Philippon J; Bataini JP; Cornu P; Grob R; Kujas M; Poisson M; Rivierez M
Neurochirurgie; 1986; 32 Suppl 1():1-84. PubMed ID: 3724947
[No Abstract] [Full Text] [Related]
12. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of intracranial meningiomas, with special reference to radiotherapy.
Yamashita J; Handa H; Iwaki K; Abe M
Surg Neurol; 1980 Jul; 14(1):33-40. PubMed ID: 7414483
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
16. Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison.
Jim HS; Small BJ; Patterson S; Salup R; Jacobsen PB
Support Care Cancer; 2010 Jan; 18(1):21-7. PubMed ID: 19343369
[TBL] [Abstract][Full Text] [Related]
17. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
18. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
19. Uncommon course of carcinoma of the prostate after radical prostatectomy and luteinizing hormone-releasing hormone analogue therapy.
Pauer W; Eckerstorfer GM
J Urol; 1998 Oct; 160(4):1432-3. PubMed ID: 9751377
[No Abstract] [Full Text] [Related]
20. Gastrin-releasing peptide: predictor of castration-resistant prostate cancer?
Heinrich E; Probst K; Michel MS; Trojan L
Prostate; 2011 May; 71(6):642-8. PubMed ID: 20945407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
